Kurzfassung

Bone metastasis is a major driver of morbidity and mortality in advanced prostate cancer and is critically mediated by CXCR4/CXCL12 signaling. We develop a human microfluidic 3D bone cancer-on-chip model that recapitulates early metastatic seeding under physiologically relevant conditions. This platform enables functional validation of CXCR4 antagonists as anti-metastatic interventions. Our approach aims to accelerate translation of metastasis-preventive therapies into clinical application.